AbbVie submits regulatory applications to FDA and EMA for upadacitinib in vitigo

AbbVie (ABBV) has submitted applications for a new indication to the FDA and European Medicines Agency, or EMA, for upadacitinib for the treatment of adult and adolescent patients living with non-segmental vitiligo,or NSV. The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with NSV. NSV, the most common form of vitiligo afflicting approximately 84% of patients, is marked by symmetrical and bilateral depigmented white patches and is prone to unpredictable progression even after long periods of stability. There are currently no approved systemic medicines for achieving these treatment goals in vitiligo.